A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity
NCT03842202 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72
Last updated 2020-12-24
Summary
This study will look at how the emptying of the participant's stomach after a meal is affected by semaglutide (a new medicine) compared to a "dummy" medicine. In addition, the study will also look at the effect of semaglutide on the participant's appetite and energy intake. Participants will either get semaglutide or "dummy" medicine - which treatment any participant gets is decided by chance. Participants will take 1 injection per week. The study medicine is injected with a thin needle in the stomach, thigh or upper arm. The study will last for about 27 weeks (from first treatment to last check-up). Participants will have 8 visits at the clinic with the study doctor.
Conditions
Interventions
- DRUG
-
Participants will receive gradually increasing doses of semaglutide (subcutaneous \[s.c.\], in the thigh, abdomen or upper arm) injection once weekly, until they reach a dose of level of 2.4 mg, which they will continue for 5 weeks.
- DRUG
-
Participants will receive once weekly injections of semaglutide matched placebo.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Reporting Anchor and Disclosure (1452) · Novo Nordisk A/S
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-02-15
- Primary Completion
- 2019-11-04
- Completion
- 2019-11-04
- FDA Drug
- Yes
Countries
- Germany
Study Locations
More Related Trials
-
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
NCT03552757 ·Status: COMPLETED ·Phase: PHASE3
-
Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
NCT03693430 ·Status: COMPLETED ·Phase: PHASE3
-
STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity
NCT03811574 ·Status: COMPLETED ·Phase: PHASE3
-
Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects
NCT05548647 ·Status: COMPLETED ·Phase: PHASE4
-
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight
NCT06207877 ·Status: COMPLETED ·Phase: PHASE1
-
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
NCT04074161 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Weekly Semaglutide Treatment on Energy Expenditure
NCT06390501 ·Status: COMPLETED ·Phase: NA
-
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
NCT03574597 ·Status: COMPLETED ·Phase: PHASE3
-
Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
NCT05040971 ·Status: COMPLETED ·Phase: PHASE3
-
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
NCT03548935 ·Status: COMPLETED ·Phase: PHASE3
-
GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
NCT04779697 ·Status: COMPLETED ·Phase: PHASE1
-
A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese
NCT03574584 ·Status: COMPLETED ·Phase: PHASE1
-
A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
NCT03600480 ·Status: COMPLETED ·Phase: PHASE1
-
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
NCT02453711 ·Status: COMPLETED ·Phase: PHASE2
-
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
NCT07225816 ·Status: RECRUITING ·Phase: PHASE1
-
Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo
NCT02079870 ·Status: COMPLETED ·Phase: PHASE1
-
A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants
NCT05784402 ·Status: COMPLETED ·Phase: PHASE1
-
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
NCT05035095 ·Status: COMPLETED ·Phase: PHASE3
-
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
NCT05419726 ·Status: RECRUITING
-
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
NCT05564117 ·Status: COMPLETED ·Phase: PHASE3
-
Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity
NCT04788511 ·Status: COMPLETED ·Phase: PHASE3
-
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
NCT03707990 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity
NCT03523273 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
NCT06500429 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of How CagriSema Works on Appetite in People With Excess Body Weight
NCT06267092 ·Status: COMPLETED ·Phase: PHASE1